Profile data is unavailable for this security.
About the company
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
- Revenue in USD (TTM)0.00
- Net income in USD-9.45m
- Incorporated2005
- Employees7.00
- LocationNanoViricides Inc1 Controls DriveSHELTON 06484United StatesUSA
- Phone+1 (203) 937-6137
- Fax+1 (203) 859-5095
- Websitehttp://www.nanoviricides.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synlogic Inc | 2.78m | -37.18m | 16.90m | 6.00 | -- | 1.29 | -- | 6.09 | -4.09 | -4.09 | 0.258 | 1.12 | 0.0638 | -- | -- | 462,833.30 | -85.46 | -40.57 | -105.90 | -43.82 | -- | -- | -1,338.82 | -3,245.93 | -- | -- | 0.00 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Kazia Therapeutics Ltd (ADR) | 14.67k | -13.31m | 17.36m | 12.00 | -- | 0.1632 | -- | 1,183.23 | -80.72 | -80.72 | 0.0796 | 34.37 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 0.00 | -6.59m | 17.60m | 4.00 | -- | 4.15 | -- | -- | -0.8556 | -0.8556 | 0.00 | 0.487 | 0.00 | -- | -- | 0.00 | -149.16 | -- | -173.23 | -- | -- | -- | -- | -- | -- | -370.56 | 0.043 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -34.27m | 17.66m | 25.00 | -- | 1.24 | -- | -- | -0.9553 | -0.9553 | 0.00 | 0.3549 | 0.00 | -- | -- | 0.00 | -103.30 | -- | -150.91 | -- | -- | -- | -- | -- | -- | -260.86 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Palatin Technologies, Inc. | 2.38m | -32.35m | 17.87m | 30.00 | -- | -- | -- | 7.50 | -1.98 | -1.98 | 0.1434 | -0.3932 | 0.3252 | -- | -- | 79,470.34 | -441.31 | -55.28 | -- | -69.08 | 95.90 | -- | -1,357.06 | -1,359.14 | -- | -- | -- | -- | -7.49 | -40.52 | -23.71 | -- | 3.31 | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 18.39m | 18.00 | -- | 1.29 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.45m | 18.55m | 7.00 | -- | 1.85 | -- | -- | -0.7579 | -0.7579 | 0.00 | 0.7188 | 0.00 | -- | -- | 0.00 | -69.61 | -43.88 | -76.92 | -46.26 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.43 | -- | 16.23 | -- |
| MEI Pharma Inc | 0.00 | -46.60m | 18.66m | 28.00 | -- | 0.7499 | -- | -- | -6.99 | -6.99 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -72.25 | -21.09 | -79.28 | -23.99 | -- | -- | -- | -72.23 | -- | -- | 0.00 | -- | 33.76 | 67.75 | 155.84 | -- | -49.68 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -11.24m | 18.70m | 3.00 | -- | 5.76 | -- | -- | -0.7287 | -0.7287 | 0.00 | 0.2197 | 0.00 | -- | -- | 0.00 | -169.22 | -- | -191.76 | -- | -- | -- | -- | -- | -- | -3.32 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -2.74m | 18.75m | -- | -- | 5.63 | -- | -- | -0.2279 | -0.2279 | 0.00 | 0.2594 | 0.00 | -- | -- | -- | -92.10 | -- | -264.70 | -- | -- | -- | -- | -- | -- | -2.61 | 0.0409 | -- | -- | -- | -72.57 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -7.51m | 19.28m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Unity Biotechnology Inc | 0.00 | -19.05m | 19.71m | 19.00 | -- | 1.39 | -- | -- | -1.14 | -1.14 | 0.00 | 0.8394 | 0.00 | -- | -- | 0.00 | -32.73 | -47.21 | -38.49 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 19.79m | 11.00 | -- | 2.11 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Ibio Inc | 175.00k | -14.36m | 20.01m | 16.00 | -- | 1.07 | -- | 114.35 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| OpGen Inc | 1.96m | -22.39m | 20.04m | 100.00 | -- | -- | -- | 10.20 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
Data as of Nov 21 2024. Currency figures normalised to NanoViricides Inc's reporting currency: US Dollar USD
8.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 506.70k | 3.45% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 158.75k | 1.08% |
| Banque Lombard Odier & Cie SA (Investment Management)as of 30 Sep 2024 | 150.00k | 1.02% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 114.90k | 0.78% |
| Geode Capital Management LLCas of 30 Sep 2024 | 111.36k | 0.76% |
| Integrated Wealth Concepts LLCas of 30 Sep 2024 | 53.34k | 0.36% |
| Bridgeway Capital Management LLCas of 30 Sep 2024 | 44.04k | 0.30% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 41.91k | 0.29% |
| City National Rochdale LLCas of 30 Sep 2024 | 30.54k | 0.21% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 24.26k | 0.17% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
